重组肠激酶(rEK)是一种高纯度的重组牛肠激酶轻链片段,氨基酸序列与牛肠激酶轻链一致,有着和天然提取的肠激酶同样特异的酶切位点,切割位点Asp-Asp-Asp-Asp-Lys,可去除位于蛋白N-末端的融合蛋白,以除去不需要的融合标签,同时重组肠激酶(rEK)具有比天然酶更高的切割活性。重组肠激酶为采用重组大肠杆菌分泌表达的高纯度、高活性、高特异的牛肠激酶,不含其他蛋白酶,可以在较宽pH范围(4.5-9.5)和较宽温度范围内有效切割融合蛋白,并且在各种去垢剂和变性剂存在的条件下仍具有部分活性。本品不含标签,由于具有极高酶切活性,酶切反应使用量少,不影响下游蛋白应用,可不考虑除去。产品信息规格100U/200U/500U/1000U/5000U产品性质来源(Source)大肠杆菌表达分子量(MolecularWeight)理论值25.85kDa外观(Appearance)澄清、无色至淡黄色液体酶浓度(EnzymeConcentration)≥5U/uL活性定义(ActivityDefinition)一个活性单位定义为25°C,12-16h,LAG-1与MIP-1β(ACT II同种型)相同,Lag-1趋化吸引力单核细胞,并表现出活性作为HIV抑制因子。Recombinant Human ENA-78,5-78 aa/CXCL5

Recombinant Human ACE2/ACEH Protein,hFc Tag性能参数,分子别名(Synonyms)ACE2;ACEH;ACE-2表达区间及表达系统(Source)HumanACE2/ACEHProteinisexpressedfromHEK293withhFctagattheC-Terminus.ItcontainsGln18-Ser740.[Accession|Q9BYF1-1]分子量大小(MolecularWeight)TheproteinhasapredictedMWof109.2kDa.Duetoglycosylation,theproteinmigratesto115-130kDabasedonSDS-PAGEresult.Endotoxin)Lessthan1EUperμgbytheLALmethod.纯度(Purity)>95%asdeterminedbySDS-PAGEandHPLC.活性(Activity)ELISAData:ImmobilizedSARS-COV-2SpikeS(B.1.1.529/Omicron)Trimer,HisTagat1μg/ml(100μl/well)ontheplate.DoseresponsecurveforHumanACE2,hFcTagwiththeEC50of13.7ng/mldeterminedbyELISA.制剂(Formulation)Lyophilizedfrom0.22μmfilteredsolutioninPBS(pH7.4).Normally8%trehaloseisaddedasprotectantbeforelyophilization.重构方法(Reconstitution)Centrifugethetubebeforeopening.Reconstitutingtoaconcentrationmorethan100μg/mlisrecommended.Dissolvethelyophilizedproteinindistilledwater.Recombinant Human CD4/LEU3 (His-Avi Tag)UbcH5a/UBE2D1具有一个保守的E2催化结构域,该结构域含有一个活性位点半胱氨酸残基。

Recombinant Biotinylated Human KIR2DL1 Protein,His-Avi Tag性能参数分子别名(Synonyms)CD158A;CD158Ankat1;cl-42表达区间及表达系统(Source)BiotinylatedHumanKIR2DL1ProteinisexpressedfromHEK293withHistagandAvitagattheC-Terminus.ItcontainsHis22-Arg242.[Accession|P43626]分子量大小(MolecularWeight)TheproteinhasapredictedMWof27.1kDa.Duetoglycosylation,theproteinmigratesto48-60kDabasedonSDS-PAGEresult.(Endotoxin)Lessthan1EUperμgbytheLALmethod.纯度(Purity)>95%asdeterminedbySDS-PAGEandHPLC.制剂(Formulation)Lyophilizedfrom0.22μmfilteredsolutioninPBS(pH7.4).Normally8%trehaloseisaddedasprotectantbeforelyophilization.重构方法(Reconstitution)Centrifugethetubebeforeopening.Reconstitutingtoaconcentrationmorethan100μg/mlisrecommended.Dissolvethelyophilizedproteinindistilledwater.储存条件Theproductshouldbestoredat-25~-15℃for1yearfromdateofreceipt.2-7days,2~8°Cundersterileconditionsafterreconstitution.
Recombinant Biotinylated Human ENPP-3 Protein,His-Avi Tag性能参数分子别名(Synonyms)NPP3;E-NPP3;PD-Ibeta表达区间及表达系统(Source)BiotinylatedHumanENPP-3ProteinisexpressedfromHEK293withHistagandAvitagattheN-Terminus.ItcontainsLeu48-Ile875.[Accession|O14638]分子量大小(MolecularWeight)TheproteinhasapredictedMWof99.97kDa.Duetoglycosylation,theproteinmigratesto110-130kDabasedonSDS-PAGEresult.(Endotoxin)Lessthan1EUperμgbytheLALmethod.纯度(Purity)>95%asdeterminedbySDS-PAGEandHPLC.制剂(Formulation)Lyophilizedfrom0.22μmfilteredsolutioninPBS(pH7.4).Normally8%trehaloseisaddedasprotectantbeforelyophilization.重构方法(Reconstitution)Centrifugethetubebeforeopening.Reconstitutingtoaconcentrationmorethan100μg/mlisrecommended.Dissolvethelyophilizedproteinindistilledwater.储存条件Theproductshouldbestoredat-25~-15℃for1yearfromdateofreceipt.2-7days,2~8°Cundersterileconditionsafterreconstitution.3-6months,-85~-65℃understerileconditionsafterreconstitution.人血清白蛋白(HSA)是脂类等物质的转运载体,其主要生理功能是调节血浆pH值和维持血浆渗透压。

产品描述纤维蛋白原(Fibrinogen,Fg),即凝血因子I,分子量约340kDa,由α、β、γ三对不同多肽链组成,多肽链间以二硫键相连。α链分子量63.5kDa,β链分子量56kDa,γ链分子量47kDa,纤维蛋白原约含4%碳水化合物。纤维蛋白原参与凝血的原理:在凝血酶作用下,α链与β链分别释放出A肽与B肽,生成纤维蛋白单体。在此过程中,由于释放了酸性多肽,负电性降低,单体易于聚合成纤维蛋白多聚体,但此时单体之间借氢键与疏水键相连,尚可溶于稀酸和尿素溶液中。进一步在Ca2+与活化的ⅩⅢ因子作用下,单体之间以共价键相连,则变成稳定的不溶性纤维蛋白凝块,完成凝血过程。来源于不同物种(如来源于牛、猫、狗、豚鼠、人、绵羊、小鼠和大鼠等)的纤维蛋白原具有相似的结构和性质。因此,一般来源于一种哺乳动物的纤维蛋白原可与其他来源的凝血酶交叉反应,相反地来自一种哺乳动物蛋白的凝血酶液也可注入多种动物,发生凝血反应。SUMO蛋白酶识别完整的含有100个氨基酸的SUMO标签蛋白,并能高效地把SUMO从融合蛋白上切割下来。Transdermal Peptide
泛素蛋白是一个76个氨基酸,高度保守的核和细胞质蛋白。Recombinant Human ENA-78,5-78 aa/CXCL5
性能参数表达区间及表达系统(Source)CynomolgusCD27Ligand/CD70ProteinisexpressedfromHEK293withHistagattheN-terminal.ItcontainsGln39-Pro194.[Accession|G7PYU6-1]分子量大小(MolecularWeight)TheproteinhasapredictedMWof18.4kDa.Duetoglycosylation,theproteinmigratesto60-90kDabasedonTris-BisPAGEresult.(Endotoxin)Lessthan1EUperugbytheLALmethod.纯度(Purity)>95%asdeterminedbyTris-BisPAGE活性(Activity)ELISAData:ImmobilizedCynomolgusCD27Ligand,HisTagat2μg/ml(100μl/well)ontheplate.DoseresponsecurveforCynomolgus/RhesusmacaqueCD27,hFcTagwiththeEC50of70.8ng/mldeterminedbyELISA.制剂(Formulation)Lyophilizedfrom0.22μmfilteredsolutioninPBS(pH7.4).Normally8%trehaloseisaddedasprotectantbeforelyophilization.重构方法(Reconstitution)Centrifugetubesbeforeopening.Reconstitutingtoaconcentrationmorethan100μg/mlisrecommended.Dissolvethelyophilizedproteinindistilledwater.Recombinant Human ENA-78,5-78 aa/CXCL5
重组人KIR2DL2蛋白(Recombinant Human KIR2DL2 Protein, His-Avi Tag)是一种重要的免疫调节分子,属于杀伤细胞免疫球蛋白样受体(Killer-cell Immunoglobulin-like Receptor, KIR)家族成员,主要表达于自然杀伤细胞(NK细胞)和部分T细胞表面。KIR2DL2通过识别并结合靶细胞表面的HLA-C分子,传递抑制性信号,从而抑制NK细胞的细胞毒活性,在维持免疫耐受、抗病毒免疫及肿瘤免疫监视中发挥关键作用。该重组蛋白采用真核表达系统(如HEK293细胞)制备,确保了其天然构象和生物活性。其N端融合了His标签,便于通...